Pegylated interferon-alfa-2a monotherapy in patients infected with HCV genotype 2 and importance of rapid virological response

BMC Research Notes

Volumn 4, Issue , 2011, Pages

  Etoh, Reiko ^a   Imazeki, Fumio ^a   Kurihara, Tomoko ^a   Fukai, Kenichi ^a   Fujiwara, Keiichi ^a   Arai, Makoto ^a   Kanda, Tatsuo ^a   Mikata, Rintaro ^a   Yonemitsu, Yutaka ^a   Yokosuka, Osamu ^a  

^a CHIBA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

HEPATITIS C VIRUS; HEPATITIS C VIRUS GENOTYPE 2;

EID: 80052169694     PISSN: None     EISSN: 17560500     Source Type: Journal    
DOI: 10.1186/1756-0500-4-316     Document Type: Article

References (31)

1. Hepatitis C and hepatocellular carcinoma. Di Bisceglie AM, Hepatology 1997 3 Suppl 1 34S 38S (Pubitemid 27388069)
2. Hepatitis C virus and liver transplantation. Ahmed A, Keeffe EB, Clin Liver Dis 2001 5 1073 1090 10.1016/S1089-3261(05)70210-5 11685796 (Pubitemid 33001021)
3. New antiviral therapies for chronic hepatitis C. Kanda T, Imazeki F, Yokosuka O, Hepatol Int 2010 4 548 561 10.1007/s12072-010-9193-3 21063477
4. Peginterferon alfa-2a plus ribavirin for the treatment of dual chronic infection with hepatitis B and C viruses. Liu CJ, Chuang WL, Lee CM, Yu ML, Lu SN, Wu SS, Liao LY, Chen CL, Kuo HT, Chao YC, Tung SY, Yang SS, Kao JH, Liu CH, Su WW, Lin CL, Jeng YM, Chen PJ, Chen DS, Gastroenterology 2009 136 496 504 10.1053/j.gastro.2008.10.049 19084016
5. Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3. Shiffman ML, Suter F, Bacon BR, Nelson D, Harley H, Sola R, Shafran SD, Barange K, Lin A, Soman A, Zeuzem S, ACCELERATE Investigators, N Engl J Med 2007 357 124 134 10.1056/NEJMoa066403 17625124 (Pubitemid 47057730)
6. Peginterferon alfa-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3. Mangia A, Santoro R, Minerva N, Ricci GL, Carretta V, Persico M, Vinelli F, Scotto G, Bacca D, Annese M, Romano M, Zechini F, Sogari F, Spirito F, Andriulli A, N Engl J Med 2005 352 2609 2617 10.1056/NEJMoa042608 15972867 (Pubitemid 41007847)
7. Randomized comparison of 12 or 24 weeks of peginterferon aipha-2a and ribavirin in chronic hepatitis C virus genotype 2/3 infection. Lagging M, Langeland N, Pedersen C, Farkkila M, Buhl MR, Morch K, Dhillon AP, Also A, Hellstrand K, Westin J, Norkrans G, Hepatology 2008 47 1837 1845 10.1002/hep.22253 18454508 (Pubitemid 351945551)
8. A randomized study on Peg-interferon alfa-2a with or without ribavirin in liver transplant recipients with recurrent hepatitis C. Angelico M, Petrolati A, Lionetti R, Lenci I, Burra P, Donato MF, Merli M, Strazzabosco M, Tisone G, J Hepatol 2007 46 1009 1017 17328985 (Pubitemid 46680357)
9. Pegylated interferon alpha-2a versus standard interferon alpha-2a for treatment-nave dialysis patients with chronic hepatitis C: a randomized study. Liu CH, Liang CC, Lin JW, Chen SI, Tsai HB, Chang CS, Hung PH, Kao JH, Liu CJ, Lai MY, Chen JH, Chen PJ, Kao JH, Chen DS, Gut 2008 57 525 530 17881538
10. Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis. Heathcote EJ, Shiffman ML, Cooksley WG, Dusheiko GM, Lee SS, Balart L, Reindollar R, Reddy RK, Wright TL, Lin A, Hoffman J, De Pamphilis J, N Engl J Med 2000 343 1673 1680 10.1056/NEJM200012073432302 11106716
11. Peginterferon alfa-2a in patients with chronic hepatitis C. Zeuzem S, Feinman SV, Rasenack J, Heathcote EJ, Lai MY, Gane E, O'Grady J, Reichen J, Diago M, Lin A, Hoffman J, Brunda MJ, N Engl J Med 2000 343 1666 1672 10.1056/NEJM200012073432301 11106715
12. Combination therapy with interferon plus ribavirin for the initial treatment of chronic hepatitis C. McHutchison JG, Poynard T, Semin Liver Dis 1999 19 suppl 1 57 65 10349693
13. High sustained virologic response rate after interferon monotherapy in Japanese hepatitis C patients with a low HCV RNA titer and/or HCV genotype 2. A prospective study. Yokosuka O, Iwama S, Suzuki N, Takashi M, Hirai Y, Uchiumi K, Kimura M, Gotou N, Hino S, Hayasaka A, Kanda T, Kawai S, Fukai K, Imazeki F, Saisho H, Intervirology 2004 47 328 334 10.1159/000080876 15564744 (Pubitemid 39541279)
14. Detection of hepatitis C virus RNA by a combined reverse transcription-polymerase chain reaction assay. Young KKY, Resnick RM, Myers TW, J Clin Microbiol 1993 31 882 886 8385151 (Pubitemid 23086532)
15. Quantification of hepatitis C virus in patients treated with peginterferon-alfa 2a plus ribavirin treatment by COBAS TaqMan HCV test. Kanda T, Imazeki F, Yonemitsu Y, Mikami S, Takada N, Nishino T, Takashi M, Tsubota A, Kato K, Sugiura N, Tawada A, Wu S, Tanaka M, Nakamoto S, Mikata R, Tada M, Chiba T, Kurihara T, Arai M, Fujiwara K, Kanai F, Yokosuka O, J Viral Hepat 2011 18 292 e297 10.1111/j.1365-2893.2010.01409.x 21129130
16. Antigenicities of group I and II hepatitis virus polypeptides-molecular basis of diagnosis. Tsukiyama-Kohara K, Yamaguchi K, Maki N, Ohta Y, Miki K, Mizokami M, Ohba K, Tanaka S, Hattori N, Nomoto A, Kohara M, Virology 1993 192 430 437 10.1006/viro.1993.1058 7678473
17. Significance of specific antibody assay for genotyping of hepatitis C virus. Tanaka T, Tsukiyama-Kohara K, Yamaguchi K, Yagi S, Tanaka S, Hasegawa A, Ohta Y, Hattori N, Kohara M, Hepatology 1994 19 1347 1353 10.1002/hep.1840190605 7514558 (Pubitemid 24166452)
18. Sequence variability in the 5' non-coding region of hepatitis C virus: identification of a new virus type and restrictions on sequence diversity. Simmonds P, McOmish F, Yap PL, Chan SW, Lin CK, Dusheiko G, Saeed AA, Holmes EC, J Gen Virol 1993 74 661 668 10.1099/0022-1317-74-4-661 8385694 (Pubitemid 23113369)
19. Classification of chronic hepatitis: diagnosis, grading and staging. Desmet VJ, Gerber M, Hoofnagle JH, Manns M, Scheuer PJ, Hepatology 1994 19 1513 1520 10.1002/hep.1840190629 8188183 (Pubitemid 24166476)
20. Role of interleukin-28B polymorphisms in the treatment of hepatitis C virus genotype 2 infection in Asian patients. Yu ML, Huang CF, Huang JF, Chang NC, Yang JF, Lin ZY, Chen SC, Hsieh MY, Wang LY, Chang WY, Li YN, Wu MS, Dai CY, Juo SH, Chuang WL, Hepatology 2011 53 7 13 10.1002/hep.23976 21254157
21. Meta-Analysis of Interferon Randomized Trials in the treatment of Viral Hepatitis C: Effects of Dose and Duration. Poynard T, Leroy V, Cohard M, Thevenot T, Mathurin P, Opolon P, Zarski JP, Hepatology 1996 24 778 789 10.1002/hep.510240405 8855176 (Pubitemid 26334273)
22. Pretreatment serum hepatitis C virus RNA levels and hepatitis C virus genotype are the main and independent prognostic factors of sustained response to interferon alfa therapy in chronic hepatitis C. Martinot-Peignoux M, Marcellin P, Pouteau M, Castelnau C, Boyer N, Poliquin M, Degott C, Descombes I, Le Breton V, Milotova V, et al. Hepatology 1995 22 1050 1056 7557850
23. Significance of serum hepatitis C virus RNA levels in chronic hepatitis C. Lau JY, Davis GL, Kniffen J, Qian KP, Urdea MS, Chan CS, Mizokami M, Neuwald PD, Wilber JC, Lancet 1993 341 1501 1504 10.1016/0140-6736(93)90635-T 8099380 (Pubitemid 23168644)
24. An IL28B polymorphism determines treatment response of hepatitis C virus genotype 2 or 3 patients who do not achieve a rapid virologic response. Mangia A, Thompson AJ, Santoro R, Piazzolla V, Tillmann HL, Patel K, Shianna KV, Mottola L, Petruzzellis D, Bacca D, Carretta V, Minerva N, Goldstein DB, McHutchison JG, Gastroenterology 2010 139 821 827 10.1053/j.gastro.2010.05.079 20621700
25. Importance of IL28B gene polymorphisms in hepatitis C virus genotype 2 and 3 infected patients. Sarrazin C, Susser S, Doehring A, Lange CM, Muller T, Schlecker C, Herrmann E, Lotsch J, Berg T, J Hepatol 2011 54 415 421 10.1016/j.jhep.2010.07.041 21112657
26. Predictive value of the IL28B polymorphism on the effect of interferon therapy in chronic hepatitis C patients with genotypes 2a and 2b. Kawaoka T, Hayes CN, Ohishi W, Ochi H, Maekawa T, Abe H, Tsuge M, Mitsui F, Hiraga N, Imamura M, Takahashi S, Kubo M, Tsunoda T, Nakamura Y, Kumada H, Chayama K, J Hepatol 2011 54 408 414 10.1016/j.jhep.2010.07.032 21112660
27. Association of IL28B variants with response to pegylated-interferon alpha plus ribavirin combination therapy reveals intersubgenotypic differences between genotypes 2a and 2b. Sakamoto N, Nakagawa M, Tanaka Y, Sekine-Osajima Y, Ueyama M, Kurosaki M, Nishida N, Tamori A, Yuki NS, Itsui Y, Azuma S, Kakinuma S, Hige S, Itoh Y, Tanaka E, Hiasa Y, Izumi N, Tokunaga K, Mizokami M, Watanabe M, Ochanomizu-Liver Conference Study Group, J Med Virol 2011 83 871 878 10.1002/jmv.22038 21360545
28. Interleukin 28B gene variation at rs12979860 determines early viral kinetics during treatment in patients carrying genotypes 2 or 3 of hepatitis C virus. Lindh M, Lagging M, Farkkila M, Langeland N, Morch K, Nilsson S, Norkrans G, Pedersen C, Buhl MR, Westin J, Hellstrand K, J Infect Dis 2011 203 1748 1752 10.1093/infdis/jir193 21606533
29. Simple assay based on restriction fragment length polymorphism associated with IL28B in chronic hepatitis C patients. Nakamoto S, Kanda T, Imazeki F, Wu S, Arai M, Fujiwara K, Yokosuka O, Scand J Gastroenterol 2011 46 955 961 10.3109/00365521.2011.574731 21529139
30. Response to peginterferon-alfa 2b and ribavirin in Japanese patients with chronic hepatitis C genotype 2. Kanda T, Imazeki F, Azemoto R, Yonemitsu Y, Mikami S, Kita K, Takashi M, Sunaga M, Wu S, Nakamoto S, Tawada A, Arai M, Kato K, Yoshida Y, Koma Y, Fujiwara K, Fukai K, Suzuki N, Yokosuka O, Dig Dis Sci 2011
31. Treatment of hepatitis C virus infection: updated Swedish Consensus recommendations. Lagging M, Wejstal R, Uhnoo I, Gerden B, Fischler B, Friman S, Josephson F, Karlstrom O, Sangfelt P, Schvarz R, Weiland O, Swedish Consensus Group, Scand J Infect Dis 2009 41 389 402 10.1080/00365540902998271 20001276